Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 4

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 OF CHANGES IN EQUITY(Unaudited)

Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' EquityNoncontrolling InterestsTotal Equity(in thousands except share data)SharesAmountSharesAmountBalance at January 1, 202563,077,431 $6 841,269 $— $677,415 $(235,593)$4,997 $446,825 $6,566 $453,391 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— — — — 2,279 — — 2,279 11 2,290 Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares111,949 — (111,949)— 841 — 10 851 (851)— Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee93,347 — — — 129 — — 129 (9)120 Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan191,526 — — — — — — — — — Net loss for the three months ended March 31, 2025— — — — — (39,944)— (39,944)(615)(40,559)Other comprehensive loss— — — — — — (2,620)(2,620)(41)(2,661)Balance at March 31, 202563,474,253 $6 729,320 $— $680,664 $(275,537)$2,387 $407,520 $5,061 $412,581 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— $— — $— $3,298 $— $— $3,298 $11 $3,309 Net loss for the three months ended June 30, 2025— $— — $— $— $(55,220)$— $(55,220)$(831)$(56,051)Other comprehensive loss— $